Microglia targeting improves cmv-related neurological outcomes

The present invention relates the field of CMV and CMV related diseases. Using a powerful rat model of CMV infection of the embryonic brain, the inventors have looked for the existence of postnatal neurological and neurosensory manifestations, and have tested whether the early pharmacological targeting of microglia during pregnancy impacts on postnatal phenotypes. Particularly, the inventors tested the clodronate and the doxycycline and showed that these compounds improve the postnatal outcome of the baby. Thus, the invention relates to a compound which modifies the microglia for use in the treatment of CMV related diseases in a subject in need thereof.

Keywords: Neurology - CMV infection - targeting microglia
Patent Application number: EP17306455.1
Inventors:
Nadine BRUNEAURobin CLOARECSylvian BAUERPierre SZEPETOWSKI
Publications:
Front Cell Neurosci. 2018 Mar 6;12:55. doi: 10.3389/fncel.2018.00055

Reference:

BIO17337-T1

Business Developper
contact
Anne COCHI
Anne COCHI
Business Development Manager
Patent filling date: 23-10-2017

You might also be interested in